13/04/2022

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Abstract

BACKGROUND

With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine, several countries have begun giving at-risk persons a fourth vaccine dose.

Matéria original

Anterior

PipeCoV: a pipeline for SARS-CoV-2 genome assembly, annotation and variant identification
Próxima

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis